Registrieren
Registierung erfolgt in Kürze...
Details werden geladen...
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer | The Manila Times
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
Ähnliche Seiten
OPUS 4 | AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2026
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/130976
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | The Manila Times
https://www.manilatimes.net/2026/06/04/tmt-newswire/globenewswire/iovances-amtagvi-lifileucel-granted-approval-for-the-treatment-of-advanced-melanoma-in-australia/2358282
Why FDA approval for vepdegestrant is a major shift in cancer therapy - The Hindu
https://www.thehindu.com/sci-tech/science/why-fda-approval-for-vepdegestrant-is-a-major-shift-in-cancer-therapy/article71188088.ece
Novocure's Optune Pax Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
https://www.finanznachrichten.de/nachrichten-2026-06/68902814-novocure-s-optune-pax-receives-ce-mark-for-the-treatment-of-locally-advanced-pancreatic-cancer-004.htm
Azurity Pharmaceuticals Announces FDA Approval of Aprepitant Injectable Emulsion, Expanding Access to Critical Supportive Oncology Care | The Manila Times
https://www.manilatimes.net/2026/06/25/tmt-newswire/globenewswire/azurity-pharmaceuticals-announces-fda-approval-of-aprepitant-injectable-emulsion-expanding-access-to-critical-supportive-oncology-care/2373133